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Abstract: Prescription and administration of pro re nata (PRN) medications has remained a poorly 
discussed area of the international literature regarding ethical tenets influencing this type of medi-
cation practice. In this commentary, ethical tenets of PRN medicines management from the clinical 
perspective based on available international literature and published research have been discussed. 
Three categories were developed by the authors for summarising review findings as follows: ‘ben-
efiting the patient’, ‘making well-informed decision’, and ‘follow up assessment’ as pre-interven-
tion, through-intervention, and post-intervention aspects, respectively. PRN medicines manage-
ment is mainly intertwined with the ethical tenets of beneficence, nonmaleficence, dignity, auton-
omy, justice, informed consent, and error disclosure. It is a dynamic process and needs close collab-
oration between healthcare professionals especially nurses and patients to prevent unethical prac-
tice.  
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1. Introduction 
Medicines management is a complex process and has a multidisciplinary identity 
indicating the need for close collaboration between healthcare professionals including 
physicians, pharmacists, nurses, and patients [1]. The main tool for an effective collabora-
tion is interaction between healthcare providers that can reduce adverse drug events 
given the significance of communication lines in the prevention of medications errors [2].  
Ambiguous orders, incorrect interpretation of orders, and inappropriate monitoring 
of medications reflect insufficient and ineffective multidisciplinary collaboration between 
healthcare professionals involved in the medication process that perpetuates medication 
errors [3,4].  
The multidisciplinary healthcare team can optimise medicines management in terms 
of the reduction of polypharmacy, improvement of adherence to medications, and bal-
ancing risks and benefits of medications [5]. Systematic assessment and monitoring of the 
medication process and related side effects and adverse drug reaction (ADRs) can mini-
mise the possibility of errors [6]. The collaborative approach has great potential to im-
prove medication safety if it is cohesive and is practiced based on clearly designed roles 
and responsibilities [7]. The best outcome of the medication process is achieved when 
pharmacists, physicians and nurses undertake their assigned roles and collaborate to en-
sure clinical medication safety [8,9]. 
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2. PRN Medicines Management 
Pro re nata (PRN) has been defined as the administration of medications by the nurse 
based on the patient’s immediate needs for medications rather than at routine and prede-
termined times [10,11]. The physician prescribes the medication, and the nurse makes a 
decision on its administration based on the patient’s request to receive medications. The 
nurse's decision-making is based on creating a mutual understating and feeling of respon-
sibility between the patient and the nurse [11–13]. Additionally, the nurse has the great 
responsibility of documenting the medication process and reporting adverse events, near 
misses and errors to pharmacists [14] who have the required authority to withhold medi-
cations in the best interest of the patient and perform related follow up discussions with 
the physician [15,16]. 
Common medications used as PRN are psychotropic, psycholeptic, antipsychotics, 
neuroleptics, anxiolytics, sedatives, hypnotics, and analgesics [11–13,17,18]. Our 
knowledge of errors associated with PRN medications is very limited. However, not act-
ing on PRN medication requests by the patient within 15 minutes has been defined as the 
medication error [19]. Additionally, 9–40% of medication errors in intensive care units 
have been attributed to PRN medications [20] and, in general wards, 23% of PRN medi-
cations are accompanied with an unclear indication for prescription and administration. 
Moreover, 36% of PRN medications are not stopped though they are not administered at 
all during hospitalisation [21].  
PRN medicines management provides a flexible care condition for the patient to sub-
mit the medication request to the nurse with the aim of relieving his/her physical and 
psychological suffering who has the legal and ethical responsibility to decide on the ap-
propriateness of pharmacological interventions based on the physician order [22,23]. 
There is no strong evidence from randomised clinical trials to support the process of PRN 
medications’ prescription and administration. Therefore, it is often practised based on 
clinical experience and work routines [24].  
It is also influenced by ethical tenets, law, healthcare policies, institutional guidelines, 
patients’ and healthcare professionals’ values and beliefs [17,18]. Moreover, socio-demo-
graphic characteristics of the patient as gender, ethnicity, and education level can influ-
ence PRN medication practice. For instance, old age, female gender, being black, living in 
a one-person household, and poor health literacy can be more associated with the use of 
PRN medications [25,26].  
Nevertheless, there is no integrated and comprehensive knowledge about which eth-
ical tenets influence PRN medications. Therefore, the aim of this commentary was to dis-
cuss ethical tenets influencing PRN medicines management from the clinical perspective.  
3. Ethics and PRN Medicines Management  
Our review findings regarding ethical tenets influencing PRN medicines manage-
ment from the clinical perspective have been summarised using the following author-
made categories: ‘benefiting the patient’, ‘making well-informed decision’, and ‘follow up 
assessment’ as pre-intervention, through-intervention, and post-intervention aspects, re-
spectively (Figure 1). Each category describes the clinical process of PRN medicines man-
agement in connection to ethics and discusses how unethical practice can be avoided. 




Figure 1. PRN medicines management and ethics from the clinical perspective. 
3.1. Ethical Tenets of Benefiting the Patient 
3.1.1. Beneficence and Nonmaleficence 
PRN medicines management starts with the patient’s verbal request for medications 
aiming at relieving his/her physical and/or mental suffering. The observation of the pa-
tient’s clinical sign and behavioural clues also can help the nurse identify his/her need for 
PRN medications [27].  
As the pre-intervention aspect of PRN medication practice, the nurse should consider 
the ethical tenets of beneficence and nonmaleficence indicating his/her professional obli-
gation to do no harm. The nurse should refrain from exposing the patient to any health-
related negative consequences of medications and take all precautionary measures to 
meet the patient’s need, but not to add to his/her suffering, through selecting the most 
suitable medications [28,29]. 
Despite the benefits of PRN medications, their inappropriate and unnecessary pre-
scription and administration can be associated with polypharmacy (≥5 medicines), over-
dosing, over- or under-use, and the patient’s disagreement given administration without 
the full disclosure of information about medications to the patient [30,31]. The nurse 
should play the role of the patient’s advocate and prioritise the benefit to the patient 
through the assessment of medication effectiveness, probability of harm, side effects and 
adverse reactions, and their impact on patient’s wellbeing and health, before making a 
decision on medication administration. 
The use of PRN medications should be both evidenced-based and patient-oriented to 
have ethical support and legitimacy for application in practice. The short-term effect of 
PRN medications and their long-term harm should be balanced. The use of PRN medica-
tions should not only be grounded in the empirical evidence of treatment efficacy, but also 
should be grounded in personal values to enable taking moral decisions. Instrumental 
rationality as the pursuit of any means for achieving desirable results is the dominant 
mode of thought in the current time that focuses mostly on the aim and outcome of 
healthcare interventions. However, to assess whether to prescribe and administer PRN 
medications, ethical tenets state that the nurse should go beyond instrumental rationality 
and consider the full range of humanistic possibilities [32], with the consideration of ut-
most pragmatic benefit of the medication to the patient in decision-making situations [33]. 
Nurses should assess the patient’s clinical status and ensure that his/her request for PRN 
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medications reasonably and safely can meet his/her needs and does not lead to medication 
abuse [34], especially for mentally ill and cognitively challenged patients that may have a 
higher chance of self-harm by medications [22]. 
3.1.2. Justice  
The ethical tenet of justice preserves the equal right to access to medication therapy 
in a similar manner to all patients regardless of their age, race, ethnicity, gender, and abil-
ity to pay [34,35]. Unconscious or implicit bias such as stigmatising patients can damage 
the healthcare provider–patient relationship and consequently the caring process in terms 
of making inappropriate clinical decisions leading to healthcare disparities and different 
outcomes. Healthcare providers should seek patients’ perspectives and prevent situations 
in which stereotypical and negative responses may be given to the patient’s requests [36–
38]. Nevertheless, the nurse needs to make decisions on PRN medication administration 
based on the physiological and psychological characteristics of each patient in order to 
provide individualised care [25,26]. This ethical tenet supports the need for balancing gen-
eral evidence-based practice and the selective application of such evidence in the clinical 
context of individualised care [39]. Therefore, it encompasses demographic and health-
related characteristics, perceived and expressed preferences of the patient, nurse–patient 
relationships, and care philosophy within the workplace [39]. 
PRN medicines management requires the close engagement and collaboration be-
tween the patient and the nurse. Although some patients are willing to take more respon-
sibility for their own care, some other patients prefer healthcare professionals to be more 
attentive and proactive [40].  
The patient’s perspective of the risk and benefit of medications and cost-effective-
ness, given the patient’s level of understanding and health literacy, should be sought [41]. 
Both the patient and the nurse should reach the common understanding that every in-
crease in the number of PRN medications administered during the medication round can 
increase the risk of medication errors by 15%, along with the increased possibility of ad-
verse drug events and reactions due to polypharmacy [12,42,43].  
The nurse should also resolve the ethical concerns of the use of various medications 
with different effectiveness levels and help with the selection of the most effective medi-
cation with the least harmful effect [44]. A practical strategy can be the use of medication 
guidelines that help prevent medication errors, reduce side effects and adverse reactions 
given their concentration on systemic risk reduction and potential benefits for all patients 
[45,46]. However, there is a lack of research-based PRN medicines management guide-
lines and the available suggested ones in the international literature have been developed 
based on work routines and traditions of medication practice specialised to healthcare 
settings with a low possibility of generalisation to other healthcare settings [11]. Until an 
appropriate PRN medication guideline is developed and tested, the STOPP/START crite-
ria for the medication process can also be taken into account for screening the possibility 
of abuse and preventing harm [30]. Additionally, noncompliance to PRN medications 
given their impact on the overall effectiveness of the medication process should be moni-
tored [47].  
3.2. Ethical Tenets of Making Well-Informed Decision 
3.2.1. Autonomy and Dignity 
As the through-intervention aspect, attention should be paid to the patient’s auton-
omy and dignity in order to make the appropriate decision by the nurse on the admin-
istration of PRN medications.  
The nurse has an ethical responsibility to respect the patient’s right for receiving in-
formation about PRN medications in terms of the type of medication, medication’s side 
effects, voluntary notion of taking the medication, and freedom to accept or refuse it based 
on the given information.  
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Care is a dynamic process and clinical practice moves along the continuum between 
‘autonomy’ and ‘paternalism’, as well as between ethically reflective and non-reflective 
practice [48]. Nurses often find it difficult to practice paternalistic and ignore the patient’s 
autonomy, even if their professional knowledge is contrary to the patient’s preference and 
perspective of what is the best for him/her.  
Lack of attention to and inconsideration of the patient’s perspectives when deciding 
on the process of healthcare is missed-nursing care and is interpreted by the patient as an 
unmet care need [49]. A main part of advocacy is to prioritise the patient’s healthcare 
needs and remain committed to meeting them based on his/her preferences [50].  
The patient’s autonomy is the cornerstone of moral care [51] encompassing the pa-
tient’s right to choose the suitable type of care, which creates an obligation in healthcare 
professionals to respect the patient’s choice leading to the feeling of dignity [28].  
3.2.2. Informed Consent 
Informed consent as an ethical panacea counters autocratic and paternalistic 
healthcare practice and emphasises the patient’s right to be fully informed and to be able 
to freely choose between available therapeutic modalities [52]. The patient’s lack of trust 
in medications with regard to their effectiveness is a barrier to fully comply with PRN 
medicines management [53]. The patient should be informed of the benefits of PRN med-
ications in terms of the improvement of physical and psychological symptoms and overall 
wellbeing. The patient needs clear information and support in order to make a decision 
with full consent based on accurate, complete, and unbiased information about medica-
tions. It should be delivered in a way that he/she can understand and act upon [54–56]. 
This approach enhances the patient’s self-agency, and motivation for involvement in the 
recovery process [57].  
The patient should be empowered to choose something that aligns with their own 
perspective of life and moral values [54]. It is not uncommon that the patient refuses to 
receive PRN medications for pain management, because of his/her personal beliefs and 
values or having concerns about risks associated with medications [58]. The most common 
barrier to patient participation in the medication process is his/her level of understanding 
of medications and their positive effects [59], and the common practice should be to in-
form the patient and his/her informal caregiver of the most common and serious medica-
tion’s side effects. On the other hand, not informing the patient of all types of medication 
side-effects especially rare and non-serious ones to empower the patient to decide on tak-
ing or not taking medications can undermine respect for the patient’s autonomy [60].  
The patient’s participation in decision-making for PRN medications highly depends 
on his/her mental capacity to understand information and decide upon it [17]. Sometimes 
PRN medications including sedatives are prescribed to the patient who refuses care and 
may harm himself/herself, but the medication can improve the patient’s collaboration 
with care [61]. The cases of the involuntary PRN medication administration of psycho-
tropics, hypnotics or sedatives for older people with cognitive diseases or patients with 
mental disabilities [62,63] requires the interpretation of their symptoms and behaviours 
by the nurse, but it can cause concerns, moral uncertainty and distress, especially when 
the nurse takes the paternalistic role and coerces the patient who resists receiving medi-
cations [51,64]. In such cases, open discussions with informal caregivers and families of 
the patient about dangers posed by non-adherence to PRN medications [65,66] without 
invalidating the user response to the medication suggestion is an ethical intervention and 
leads to active involvement in medication self-management [67,68].  
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3.3. Ethical Tenets of Follow Up Assessment 
Error Disclosure 
As the post-intervention aspect, the nurse’s ethical responsibility encompasses the 
continuous monitoring and follow up of the consequences of PRN medications, detection 
of errors, and assessment of their impacts on healthcare outcomes. 
Controversies surrounding errors after the administration of PRN medications by the 
nurse encompass the insufficient assessment of medication outcomes, lack of monitoring 
side effects, and inappropriate documentation with regard to the medication’s indication 
and doses [20,69].  
The patient is partner in PRN medicines management and can be involved in recog-
nising and reporting symptom improvements, medications’ side effects and adverse reac-
tions. Additionally, he/she should be motivated, informed and educated on how to report 
them, and how their reports lead to the improvement of the medication process [70,71], 
wellbeing and healthcare outcomes [72,73].  
Disclosing the consequences of the medication process with the patient and request-
ing reporting and feedback on the patient’s side demonstrates the healthcare provider’s 
respect for the patient’s dignity and involvement in decision making.  
Medication errors generally damage the patient’s trust in healthcare professionals 
[74] and the nurse has the ethical duty to acknowledge mistakes and voluntarily disclose 
them to the patient and family members and expect fair reactions during the disclosure 
process [75].  
Ethical obligations, professional guidelines, and patient safety principles all support 
the prompt disclosure of harmful medical errors [76]. Reporting and disclosing errors are 
prevailed by the ethos of silence, secrecy, and shame [77] and are often impeded by the 
perspective from which the patient’s harm is not apparent, and the error can be ignored 
and hidden. However, it can have negative implications for patient safety culture and 
creates changes in harmful medication routines [78–80]. Additionally, it serves nonmalef-
icence and beneficence to the extent that it prevents further harm to the patient or to other 
patients who may request the same medication [81] and can preserve and restore the pa-
tient’s feeling of dignity and respect [82,83]. Deprescribing as the process of withdrawal 
of inappropriate medications also can prevent the patient’s exposure to probably inappro-
priate medications [43,84].  
4. Safeguarding PRN Medicines Management in Connection to Ethical Care 
The third WHO Global Patient Safety Challenge: Medication Without Harm pro-
poses solutions to safeguard medication practice and reduce all types of medication harm 
by 50% in the next 5 years across the globe [85]. Accordingly, healthcare systems have 
been obliged to employ all their capacities to reach the goal of a safer medication process 
and avoid, prevent, or correct adverse drug events during prescribing, order communica-
tion, compounding, distribution, administration, education, follow up, and monitoring of 
medications [86]. It also includes safe administration of PRN medications by the nurse, 
which can directly improve safety of the healthcare system. The prevalence of potentially 
inappropriate medications is 5–94% with an incidence of preventable adverse medication 
events of 15/1000 person-years [65]. In Europe, the rate of medication errors has been es-
timated to be 0.3–9.1% at prescription and 1.6–2.1% at administration stages [87]. Medica-
tion errors can lead to patients’ disability and death, and an estimated healthcare cost of 
USD 42 billion annually [88]. Therefore, policies have been articulated by international 
healthcare organisations to enhance attention by healthcare systems to the problem of 
medication safety and strengthening science-based systems for improving safe medica-
tion practice [89–91].  
Discussion regarding the ethical tenets of PRN medicines management can shape the 
fundamental principles of law, indicating what is permissible to practice legally and what 
must be done to ensure the safety of medicines management [28]. For instance, the duty 
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to use knowledge and skills by healthcare staff and prevent any failure leading to patient 
harm has its root in ethics and the breach of this duty is considered negligence leading to 
legal consequences [92–94]. 
The use of health information technology has been shown to be promising in the im-
provement of the safety of the medication process [74]. For instance, online communica-
tion platforms can help with interprofessional interactions through structuralising medi-
cation reviews and making appropriate decisions on the prescription and administration 
of PRN medications without delay based on the patient’s request [95]. However, the de-
velopment of the best practice model leading to an ethical medication process and less 
patient harm requires further research [13,96].  
The nurse as pharmacovigilant intermediary agent in medicines management is re-
sponsible for the prevention and detection of adverse drug events and errors [97]. The role 
model and active-learning strategies can be used for articulating and internalising ethical 
values by the nurse and improving the nurse’s competencies regarding how to apply the 
ethical, legal, and social principles of medication safety in clinical practice [98–100].  
5. Limitations 
The gap of knowledge in the international literature regarding PRN medicines man-
agement and the insufficient number of empirical studies on the ethical considerations of 
PRN medications hindered the researchers in conducting a systematic review. However, 
the researchers performed a comprehensive and broad search in various general and spe-
cialised databases without time restrictions using different search phrases to ensure of the 
inclusion of studies on PRN and ethics in this narrative review. It should be noted that the 
selected articles were conducted in hospitals and long-term healthcare settings indicating 
heterogeneity of their focus and findings. Therefore, this might have influenced integrat-
ing their findings into our review.  
6. Conclusions 
PRN medicines management is a dynamic process with the involvement of all 
healthcare professionals and the close collaboration between the patient and the nurse, 
which is mainly intertwined with the ethical tenets of beneficence, nonmaleficence, au-
tonomy, dignity, justice, informed consent, and error disclosure. The improvement of 
PRN medicines management based on these tenets requires education and training, as 
well as the improvement of nurses’ attitudes.  
The administration of PRN medications by the nurse with the consideration of ethical 
tenets requires: 
• Prevention of harm and abuse; 
• Selection of effective medications with the least side effect and adverse reactions; 
• Creation of balance between the short- and long-term effects of medications; 
• Consideration of the patient’s perspectives and personal values; 
• Provision of information and education to the patient and family members; 
• Development of PRN guidelines; 
• Teamwork and multidisciplinary collaboration; 
• Participation of the patient and family caregivers; 
• Continuous monitoring and follow up;  
• Disclosure and reporting of medication errors, side effects and adverse reactions. 
Empirical studies should be conducted to explore nurses’ perspectives and experi-
ences of the ethical considerations of PRN medicines management in healthcare settings.  
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